Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA
Dani L. Webber(The University of Adelaide), Louise V. O’Keefe(South Australian Health and Medical Research Institute), Laura J. Hewson(The University of Adelaide), Kim M. Hemsley(South Australian Health and Medical Research Institute), Paul J. Trim(South Australian Health and Medical Research Institute), Marten F. Snel(South Australian Health and Medical Research Institute), Robert I. Richards(University of South Australia), John J. Hopwood(Women's and Children's Hospital), Amanda Choo(The University of Adelaide)
Cited by 19
Related Papers
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase
|Molecular Genetics and Metabolism|2008|216
Mutations disrupting neuritogenesis genes confer risk for cerebral palsy
|Nature Genetics|2020|174
Replacing acid α-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers
|Molecular Therapy|2004|138
Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants
|Genetics in Medicine|2022|50
Induction of Tolerance to a Recombinant Human Enzyme, Acid Alpha-Glucosidase, in Enzyme Deficient Knockout Mice
|Transgenic Research|2003|32